Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation

被引：21
作者：
Maes, BD [1 ]
Vanrenterghem, YF [1 ]
机构：
[1] Univ Hosp Gasthuisberg, Dept Nephrol, B-3000 Louvain, Belgium
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 1999年 / 14卷 / 12期
关键词：
D O I：
10.1093/ndt/14.12.2824
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：2824 / 2826
页数：3
相关论文
共 19 条
[1]  
HAKIMI J, 1993, J IMMUNOL, V151, P1075
[2]   Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody [J].
Kahan, BD ;
Rajagopalan, PR ;
Hall, M .
TRANSPLANTATION, 1999, 67 (02) :276-284
[3]   A RANDOMIZED PROSPECTIVE TRIAL OF ANTI-TAC MONOCLONAL-ANTIBODY IN HUMAN RENAL-TRANSPLANTATION [J].
KIRKMAN, RL ;
SHAPIRO, ME ;
CARPENTER, CB ;
MCKAY, DB ;
MILFORD, EL ;
RAMOS, EL ;
TILNEY, NL ;
WALDMANN, TA ;
ZIMMERMAN, CE ;
STROM, TB .
TRANSPLANTATION, 1991, 51 (01) :107-113
[4]   Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts [J].
Kovarik, J ;
Wolf, P ;
Cisterne, JM ;
Mourad, G ;
Lebranchu, Y ;
Lang, P ;
Bourbigot, B ;
Cantarovich, D ;
Girault, D ;
Gerbeau, C ;
Schmidt, AG ;
Soulillou, JP .
TRANSPLANTATION, 1997, 64 (12) :1701-1705
[5]  
KOVARIK JM, 1999, ABSTR BOOK, pA621
[6]  
KRIAA F, 1993, TRANSPLANT P, V25, P817
[7]   Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors [J].
Mulloy, LL ;
Wright, F ;
Hall, ML ;
Moore, M .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :1210-1213
[8]   Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [J].
Nashan, B ;
Moore, R ;
Amlot, P ;
Schmidt, AG ;
Abeywickrama, K ;
Soulillou, JP .
LANCET, 1997, 350 (9086) :1193-1198
[9]   Reduction of acute renal allograft rejection by daclizumab [J].
Nashan, B ;
Light, S ;
Hardie, IR ;
Lin, A ;
Johnson, JR .
TRANSPLANTATION, 1999, 67 (01) :110-115
[10]   Daclizumab rapidly saturates interleukin-2 receptor-α (CD25) on lymph node lymphocytes in children [J].
Savo, AM ;
Book, BK ;
Henson, S ;
Hakimi, J ;
Pescovitz, MD .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :1182-1183
12